Cryoport Inc (CYRX) has announced the launch of its bio-storage offering. Cryoport Biostorage will support cryogenic storage, fulfillment, and transportation of all valuable and often irreplaceable temperature-sensitive biologic material, including clinical trial samples, vaccines, stem cells, regenerative therapies, bio-markers, and immunotherapies.
Through a strategic partnership with Pacific Bio-Material Management Inc (PBMMI), Cryoport will offer storage solutions that include cGMP-compliant biorepositories at controlled temperatures and climatized systems with effective redundancies such as back-up freezers and power. Cryoport Biostorage’s service will feature extensive management and monitoring, including controlled access to commodities, periodic temperature and activity reports, as well as 21 CFR, Part 11 compliant monitoring with 24/7/365 alarm response.
Additionally, Cryoport announced the formal launch of its Laboratory Relocation Service, which further extends its offering beyond cryogenic logistics and bio-storage services to include safe and secure transport of complete laboratories. The Laboratory Relocation Service can now manage the safe, secure, and proper transportation of materials stored in the lab as well as lab equipment and instruments. Relocation projects can range in size from the relocation of a fully equipped lab to the move of a single freezer.
Cryoport Laboratory Relocation Service is headed by Tamie Joeckel, who recently joined Cryoport’s executive team as senior vice-president–client services. She has more than 25 years of pharmaceutical industry logistics experience, having worked with companies such as AmerisourceBergen, McKesson, PAREXEL, and Dohmen Life Sciences. Joeckel also oversees the company’s Temperature Controlled Logistics Consulting Division and client care.
See www.cryoport.com or www.pbmmi.com for more information.